NCT00424242View on ClinicalTrials.gov

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

September 30, 2011

Conditions
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMetastatic CancerMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesPrecancerous ConditionSecondary MyelofibrosisUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Pemetrexed

Orally beginning at 500 mg/m2 every 3 weeks until disease progression

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00424242 - Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases | Biotech Hunter | Biotech Hunter